101113) and plasma FGF21 was detected with the FGF21 ELISA (Biovendor, Ref
Preclinical studies have shown that cagrilintide is extensively metabolised and subsequently excreted as metabolites in bile and urine [data on file]
This policy reflects advice from professional bodies, such as the American College of Occupational and Environmental Medicine (ACOEM), which notes that the present availability of coverage for obesity care is piecemeal and calls for guidance on how to operationalize evidence-based behavioral, nutritional, pharmacological, and surgical obesity treatment modalities as health benefits. The ACOEM further notes that obesity represents an ongoing cost to employers and society at large in the form of current and future health care expenses, absenteeism, presenteeism, and workers compensation costs related to injuries and illnesses. OPMs 2025 Call Letter, issued January 15, 2025, identified this context of rising utilization and cost amidst inconsistent application of comprehensive, evidence-based care
That does not mean every employer is pulling back, but it does mean the benefit is moving from novelty to budget line
